The dual-targeted 177Lu-DOTA-FAPI-RGD reportedly reduced or stopped the growth of cancer lesions in 88.9 percent of advanced adenocarcinomas in a small cohort of patients with varied cancers including pulmonary, pancreatic and ovarian cancer, according to new research presented at the SNMMI conference.
Could an emerging radiopharmaceutical have an impact in treating advanced adenocarcinomas across multiple cancers?
In a new study, presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference, researchers explored the use of the dual-targeted radiopharmaceutical 177Lu-DOTA-FAPI-RGD for the treatment of advanced adenocarcinoma presentations in nine patients with a variety of cancers including ovarian, pancreatic, pulmonary and renal cancer.
Here one can see intense uptake of 177Lu-FAPI-RGD in the majority of metastatic lesions including lung and lymph node nodules with baseline 68Ga-FAPI-RGD PET/CT imaging (left) and significant tumor size reduction in PET/CT imaging obtained after two treatment cycles with 177Lu-FAPI-RGD. (Images courtesy of SNMMI.)
The study authors found that 88.9 percent of the cohort had reductions in tumor size or cessation of tumor growth. The researchers also reported no side effects and added that many patients in the cohort experienced reduced pain as well as improved appetite and quality of life.
“This first-in-human dosimetry trial of 177Lu-DOTA-FAPI-RGD highlights its potential applicability across a broad spectrum of oncological diseases. The dual-targeting radioligand, 177Lu-DOTA-FAPI-RGD, exhibited an acceptable safety profile, significant tumor uptake and retention, and a promising therapeutic response,” noted lead study author Jialin Xiang, a PhD student at Peking Union Medical College Hospital in Beijing, China, and colleagues.
(Editor’s note: For additional coverage of news and research from the SNMMI conference, click here.)
The researchers emphasized that the significant uptake of 177Lu-DOTA-FAPI-RGD and its long retention facilitated high targeted dosing, citing 4.3 Gy/GBq for lung metastases as an example.
“The beauty of this drug is that it stays in tumors for days, allowing prolonged damage to cancer cells. It offers real hope for patients with advanced cancers who have exhausted other treatment options,” added Xiang.
(Editor’s note: For related content, see “Can CT-Based AI Help Predict Renal Function Decline After Radioligand Therapy for mCRPC?,” “What SPECT/CT May Reveal About Early Treatment Response for Pluvicto in Patients with mCRPC” and “New Study Shows Impact of Tau-Positive PET in Risk Stratification for Dementia and Alzheimer’s Disease.”)
Reference
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
SNMMI: Can Multimodal Monitoring Bolster Outcomes with Pluvicto in Treating mCRPC?
June 22nd 2025Multimodal treatment monitoring, including SPECT/CT exams 24 hours after treatment with Lu-177 PSMA-617, may have facilitated significantly shorter therapy durations and reduced side effects in patients with mCRPC, according to a two-year study presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
GE HealthCare Unveils Enhanced LesionID Pro at SNMMI Conference
Published: June 21st 2025 | Updated: June 21st 2025Emphasizing a zero-click experience, the updated LesionID Pro software, to be introduced at the SNMMI conference, reportedly provides AI-powered automated insights into whole-body tumor burden with PET and SPECT imaging.
ASCO: Study Reveals Significant Racial/Ethnic Disparities with PSMA PET Use for Patients with mPCa
May 30th 2025Latinx patients with metastatic prostate cancer were 63 percent less likely than non-Hispanic White patients to have PSMA PET scans, according to a study of 550 patients presented at the American Society of Clinical Oncology (ASCO) conference.